Urinary Obstruction Medication

  • Author: Michael A Policastro, MD; Chief Editor: Erik D Schraga, MD   more...
 
Updated: Apr 19, 2011
 

Medication Summary

Medical therapy for benign prostate hypertrophy (BPH) has provided a very successful alternative to surgical therapy, whose risks include anesthesia, infection, impotence, incontinence, consistent failure to restore normal flow, and frequent necessity for retreatment.

Medical therapy should not be offered to individuals presenting with absolute indications for surgical intervention.

Indications for surgical prostatectomy are recurrent urinary retention, recurrent UTIs, renal insufficiency, bladder calculi, and recurrent gross hematuria.

Next

Alpha1-adrenoceptor antagonists

Class Summary

The rationale for alpha-blockers in the treatment of BPH is based on the fact that smooth muscle accounts for 40% of the hypertrophied prostatic mass. The basal tone of prostatic smooth muscle is increased significantly by stimulation of alpha1-adrenergic receptors. Alpha-blockers relieve bladder obstruction from BPH by decreasing tonic contraction of prostatic smooth muscle.

Recent molecular studies have identified 3 subtypes of alpha1 receptors. The alpha1-AR subtype is specific for prostatic smooth muscle. Tamsulosin is a selective alpha1-AR antagonist. Recently, a new alpha1-AR antagonist, silodosin (Rapaflo), was approved.

View full drug information

Prazosin (Minipress)

 

Treats prostatic hypertrophy. Improves urine flow rates by relaxing smooth muscle. This relaxation produced by blocking alpha1-adrenoceptors in bladder neck and prostate. When increasing dosages, give first dose of each increment at bedtime to reduce syncopal episodes. Although doses >20 mg/d usually do not increase efficacy, some patients may benefit from doses as high as 40 mg/d.

View full drug information

Terazosin (Hytrin)

 

Quinazoline compound that counteracts alpha1-induced adrenergic contractions of bladder neck, facilitating urinary flow in presence of BPH.

View full drug information

Tamsulosin (Flomax)

 

Selective alpha1-antagonist for treatment of BPH.

View full drug information

Alfuzosin (UroXatral)

 

Alpha1-adrenoceptors blocker in the prostate. Blockade of adrenoceptors may cause smooth muscles in bladder neck and prostate to relax, resulting in improvement in urine flow rate and reduction in symptoms of BPH.

View full drug information

Silodosin (Rapaflo)

 

Selectively antagonizes postsynaptic alpha1-adrenergic receptors in prostate, bladder base, prostatic capsule, and prostatic urethra. This action induces smooth muscle relaxation and improves urine flow. Indicated for signs and symptoms of benign prostatic hyperplasia.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Michael A Policastro, MD  Assistant Professor of Emergency Medicine, Fellow in Medical Toxicology, Department of Emergency Medicine, University of Cincinnati; Consulting Staff, Department of Emergency Medicine, Jewish Hospital, Health Alliance

Michael A Policastro, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Emergency Physicians, American College of Medical Toxicology, Society for Academic Emergency Medicine, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Coauthor(s)

Richard H Sinert, DO  Associate Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, Research Director, State University of New York College of Medicine; Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center

Richard H Sinert, DO is a member of the following medical societies: American College of Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Pilar Guerrero, MD  Assistant Professor, Department of Emergency Medicine, John H Stroger Jr Hospital, Cook County Hospital

Disclosure: Nothing to disclose.

Specialty Editor Board

David S Howes, MD  Professor of Medicine and Pediatrics, Section Chief and Emergency Medicine Residency Program Director, University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine

David S Howes, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Physicians-American Society of Internal Medicine, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Richard H Sinert, DO  Associate Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, Research Director, State University of New York College of Medicine; Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center

Richard H Sinert, DO is a member of the following medical societies: American College of Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

John D Halamka, MD, MS  Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Erik D Schraga, MD  Staff Physician, Department of Emergency Medicine, Mills-Peninsula Emergency Medical Associates

Disclosure: Nothing to disclose.

References

  1. de la Rosette JJ, Witjes WP, Schafer W, et al. Relationships between lower urinary tract symptoms and bladder outlet obstruction: results from the ICS-"BPH" study. Neurourol Urodyn. 1998;17(2):99-108. [Medline].

  2. Christensen J, Ostri P, Frimodt-Moller C, Juul C. Intravesical pressure changes during bladder drainage in patients with acute urinary retention. Urol Int. 1987;42(3):181-4. [Medline].

  3. Gould F, Cheng CY, Lapides J. Comparison of rapid versus slow decompression of the distended urinary bladder. Investigative urology. Sep 1976;14 (2):156-8. [Medline].

  4. Bartosh SM. Medical management of pediatric stone disease. Urol Clin North Am. Aug 2004;31(3):575-87, x-xi. [Medline].

  5. Batlle DC, Arruda JA, Kurtzman NA. Hyperkalemic distal renal tubular acidosis associated with obstructive uropathy. N Engl J Med. Feb 12 1981;304(7):373-80. [Medline].

  6. Becker A, Baum M. Obstructive uropathy. Early Hum Dev. Jan 2006;82(1):15-22. [Medline].

  7. Belal M, Abrams P. Noninvasive methods of diagnosing bladder outlet obstruction in men. Part 1: Nonurodynamic approach. J Urol. Jul 2006;176(1):22-8. [Medline].

  8. Berrocal T, Lopez-Pereira P, Arjonilla A, Gutierrez J. Anomalies of the distal ureter, bladder, and urethra in children: embryologic, radiologic, and pathologic features. Radiographics. Sep-Oct 2002;22(5):1139-64. [Medline].

  9. Bosniak MA, Megibow AJ, Ambos MA, et al. Computed tomography of ureteral obstruction. AJR Am J Roentgenol. Jun 1982;138(6):1107-13. [Medline].

  10. Catalano C, Pavone P, Laghi A, et al. MR pyelography and conventional MR imaging in urinary tract obstruction. Acta Radiol. Mar 1999;40(2):198-202. [Medline].

  11. Chapple CR, Baert L, Thind P, et al. Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Eur Urol. 1997;32(4):462-70. [Medline].

  12. Chevalier RL. Pathogenesis of renal injury in obstructive uropathy. Curr Opin Pediatr. Apr 2006;18(2):153-60. [Medline].

  13. Chu J. Genitourinary principles. In: Goldfrank's Toxicologic Emergencies. 8th ed. 2006: 442-56.

  14. Dal Canton A, Corradi A, Stanziale R, et al. Glomerular hemodynamics before and after release of 24-hour bilateral ureteral obstruction. Kidney Int. Apr 1980;17(4):491-6. [Medline].

  15. Dalgic A, Boyvat F, Karakayali H, et al. Urologic complications in 1523 renal transplantations: The Baskent University experience. Transplant Proc. Mar 2006;38(2):543-7. [Medline].

  16. De Luca GC, Wijdicks EF. Images in clinical medicine. Agitation associated with acute bladder obstruction. N Engl J Med. Oct 21 2010;363(17):1656. [Medline].

  17. Decramer S, Wittke S, Mischak H, et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med. Apr 2006;12(4):398-400. [Medline].

  18. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999;36(1):1-13. [Medline].

  19. Feinfeld DA, Anthony VL. Renal principles. In: Goldfrank's Toxicologic Emergencies. 8th ed. 2006: 427-42.

  20. Gustilo-Ashby AM, Jelovsek JE, Barber MD, et al. The incidence of ureteral obstruction and the value of intraoperative cystoscopy during vaginal surgery for pelvic organ prolapse. Am J Obstet Gynecol. May 2006;194(5):1478-85. [Medline].

  21. Hoffman LM, Suki WN. Obstructive uropathy mimicking volume depletion. JAMA. Nov 1 1976;236(18):2096-7. [Medline].

  22. Ilbeigi P, Lombardo S, Sadeghi-Nejad H. Unusual cause of obstructive uropathy. Int Urol Nephrol. 2005;37 (3):505-6. [Medline].

  23. Kessler TM, Gerber R, Burkhard FC, et al. Ultrasound assessment of detrusor thickness in men-can it predict bladder outlet obstruction and replace pressure flow study?. J Urol. Jun 2006;175(6):2170-3. [Medline].

  24. Kilby MD, Daniels JP, Khan K. Congenital lower urinary tract obstruction: to shunt or not to shunt?. BJU Int. Jan 2006;97(1):6-8. [Medline].

  25. Levin RM, Longhurst PA, Whitbeck C, Korstanje C. The effect of tamsulosin on the response of the rabbit bladder to partial outlet obstruction. Neurourol Urodyn. 2006;25(1):89-94. [Medline].

  26. Louca G, Liberopoulos K, Fidas A, et al. MR urography in the diagnosis of urinary tract obstruction. Eur Urol. Feb 1999;35(2):102-8. [Medline].

  27. Matlaga BR, Assimos DG. Urologic manifestations of nonurologic disease urolithiasis. Urol Clin North Am. Feb 2003;30(1):91-9. [Medline].

  28. Misseri R, Rink RC, Meldrum DR, Meldrum KK. Inflammatory mediators and growth factors in obstructive renal injury. J Surg Res. Jun 15 2004;119(2):149-59. [Medline].

  29. Moudouni SM, Tligui M, Doublet JD, et al. Laparoscopic excision of seminal vesicle cyst revealed by obstruction urinary symptoms. Int J Urol. Mar 2006;13(3):311-4. [Medline].

  30. O'Reilly PH, Lawson RS, Shields RA, Testa HJ. Idiopathic hydronephrosis--the diuresis renogram: a new non-invasive method of assessing equivocal pelvioureteral junction obstruction. J Urol. Feb 1979;121(2):153-5. [Medline].

  31. Powers TA, Grove RB, Bauriedel JK, et al. Detection of obstructive uropathy using 99mtechnetium diethylenetriaminepentaacetic acid. J Urol. Nov 1980;124(5):588-92. [Medline].

  32. Reynard JM. Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents?. Curr Opin Urol. Jan 2004;14(1):13-6. [Medline].

  33. Rodriguez RA. Renal toxicology. In: Occupational & Environmental Medicine. 2nd ed. 1997: 355-67.

  34. Rose JG, Gillenwater JY. Pathophysiology of ureteral obstruction. Am J Physiol. Oct 1973;225(4):830-7. [Medline].

  35. Rugo HS, Fischman ML. Occupational cancer. In: Occupational & Environmental Medicine. 2nd ed. 1997: 235-70.

  36. Rule AD, Lieber MM, Jacobsen SJ. Is benign prostatic hyperplasia a risk factor for chronic renal failure?. J Urol. Mar 2005;173(3):691-6. [Medline].

  37. Tsai JD, Huang FY, Lin CC, et al. Intermittent hydronephrosis secondary to ureteropelvic junction obstruction: clinical and imaging features. Pediatrics. Jan 2006;117(1):139-46. [Medline].

  38. Wille-Gussenhoven MJ, de Bock GH, de Beer-Buijs MJ, et al. Prostate symptoms in general practice: seriousness and inconvenience. Scand J Prim Health Care. Mar 1997;15(1):39-42. [Medline].

  39. Woderich R, Fowler CJ. Management of lower urinary tract symptoms in men with progressive neurological disease. Curr Opin Urol. Jan 2006;16(1):30-6. [Medline].

  40. Zeidel ML, Pirtskhalaishvili G. Urinary tract obstruction. In: Brenner & Rector's The Kidney. 7th ed. 2004.

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.